Categories: AlternativeDesignDevelopmentHardwareMedTechTechnology
TRicares’s objective develop a percutaneous medical device to treat tricuspid valves failure
Investors 4
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.09.2022 | Series C | $46.9M | - |
| 04.06.2018 | Series B | $25.74M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.09.2022 | TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation | TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
Paris, France and Munich, Germany, September 15, 2022 – TRiCares SAS (“TRiCares”) a pr... |
| 15.09.2022 | TRiCares Raises €47m in a First Closing of its Series C | The proceeds of this financing will primarily be used to continue the development of the company’s transfemoral tricuspid heart valve replacement system (“Topaz”) up through to the application for a pivotal investigational device exemption ... |
| 05.07.2021 | TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System | TRiCares SAS (“TRiCares”), today is pleased to announce the successful first in human implantations of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”). |
| 04.06.2018 | TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation | Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a €22 Million ($25.4... |
| 04.06.2018 | TRiCares closes €22 million Series B financing round | TRiCares today announced the successful completion of a €22 million Series B financing round to fund the development of minimally invasive treatment of tricuspid regurgitation. Proceeds from the financing will be used to advance product dev... |
Reviews 0
